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http://dxObjectives: Continuous-flow left ventricular assist devices have become the standard of care for patients with
heart failure requiringmechanical circulatory support as a bridge to transplant. However, data on long-term post-
transplant survival for these patients are limited. We evaluated the effect of continuous-flow left ventricular as-
sist devices on postcardiac transplant survival in the current era.
Methods: All patients who received a continuous-flow left ventricular assist device as a bridge to transplant at
a single center from June 2005 to September 2011 were evaluated.
Results:Of the 167 patients who received a continuous-flow left ventricular assist device as a bridge to transplant,
77 (46%) underwent cardiac transplantation, 27 died before transplantation (16%), and 63 (38%) remain listed
for transplantation and continued with left ventricular assist device support. The mean age of the transplanted pa-
tients was 54.5 11.9 years, 57% had an ischemic etiology, and 20%werewomen. The overall mean duration of
left ventricular assist device support before transplantation was 310 227 days (range, 67-1230 days). The mean
duration of left ventricular assist device support did not change in patientswho had received a left ventricular assist
device in the early period of the study (2005-2008, n¼ 62) comparedwith thosewho had received a left ventricular
assist device later (2009-2011, n¼ 78, 373 vs 392 days, P¼ NS). In addition, no difference was seen in survival
between those patients supported with a left ventricular assist device for fewer than 180 days or longer than 180
days before transplantation (P¼NS). The actuarial survival after transplantation at 30 days and 1, 3, and 5 years by
Kaplan-Meier analysis was 98.7%, 93.0%, 91.1%, and 88.0%, respectively.
Conclusions: The short- and long-term post-transplant survival for patients bridged with a continuous-flow left
ventricular assist device in the current era has been excellent. Furthermore, the duration of left ventricular assist
device support did not affect post-transplant survival. The hemodynamic benefits of ventricular unloading with
continuous-flow left ventricular assist devices, in addition to their durability and reduced patient morbidity, have
contributed to improved post-transplant survival. (J Thorac Cardiovasc Surg 2013;145:575-81)T
XCardiac transplantation remains the reference standard for
the treatment of patients with end-stage heart failure, al-
though its widespread application has been limited by the in-
sufficient pool of suitable donors.1 The discrepancy between
the limited availability of donor hearts and the increasing
number of patients with heart failure whose condition dete-
riorates while on the heart transplant waiting list or who
have advanced heart failure with end-organ dysfunction at
listing has led to the increasing use of left ventricular assist
devices (LVADs) as a bridge to transplant (BTT). Thus, the
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outcomes with mechanical circulatory support have
gradually improved over time owing to improvements in
device technology, the experience gained in intraoperative
and perioperative patient management, and attention to
patient selection and timing of LVAD implantation.
More recently, continuous-flow devices have rapidly be-
come the standard of care when used as a BTT, with excel-
lent outcomes reported.5,6 However, limited data have been
reported on the post-transplant survival of patients sup-
ported by continuous-flow devices. Thus, concern regarding
the effect of an additional surgical procedure on outcomes
remains. This is an important question because conflicting
reports have been published on the effect of LVADs on
post-transplant survival.7-11 The objective of the present
study was to evaluate the post-transplant survival of patients
supported by continuous-flow devices at a single center.METHODS
Patients
We evaluated all patients who received a continuous-flow LVAD as
a BTT from June 2005 through September 2011 at the University of
Minnesota Medical Center. Patients who received LVAD as destinationrdiovascular Surgery c Volume 145, Number 2 575
TABLE 1. Comparison of baseline characteristic
Variable
Transplanted
patients (n ¼ 77)
Continued with LVAD
support (n ¼ 63)
P
value
Ischemic etiology 44 (57%) 26 (41.2%) .056
Male gender 62 (80.5%) 44 (69.8%) .095
Age* 54.5  12 48  14 .006
BMI (kg/m2) 29  5.5 29.3  7.8 .057
LVAD duration* 310  227 498  370 .017
Blood type .083
A 43 22
B 5 5
AB 1 1
O 26 34
LVAD, Left ventricular assist device; BMI, body mass index. *P<.05.
Abbreviations and Acronyms
BMI ¼ body mass index
BTT ¼ bridge to transplant
INTERMACS ¼ Interagency Registry for
Mechanically Assisted Circulatory
Support
LVAD ¼ left ventricular assist device
UNOS ¼ United Network for Organ Sharing
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Xtherapy or device exchange for failing pulsatile pumps were excluded. We
identified 167 patients. Of these patients, 77 had received orthotopic heart
transplantation after continuous-flow LVAD support during the study
period. The present study focused on these 77 patients who had undergone
heart transplantation after implantation of a continuous-flow LVAD.
LVADs Used
The continuous-flow LVADs included in the present study included
HeartMate II (Thoratec Corp, Pleasanton, Calif), VentrAssist (Ventracor,
Brisbane, Australia), and HVAD (HeartWare, Framingham, Mass). The
details of the devices and their surgical implantation have been previously
described.5,12,13
Data Collection
After the patients had provided written informed consent, we collected
the baseline and follow-up data, including patient characteristics, body
mass index (BMI), blood type, chemistry panel results, and hemodynamic
parameters. After the patients were discharged from the hospital, they re-
turned to the University ofMinnesotaMedical Center for follow-up, device
review, and general status assessment.
Device Management
All patients were receiving standard heart failure therapy, including an-
tiarrhythmic therapy, as per our usual practice. Anticoagulation involved
a combination of warfarin and aspirin. The defibrillator or biventricular
pacing settings were not changed after LVAD placement. All patients un-
derwent a standard postoperative rehabilitation program.
Post-Transplant Follow-up
After transplantation, the patients were followed up on a routine basis.
Survival after transplantation was determined at 30 days and 1, 3, and
5 years. The patients were also stratified by the duration of LVAD support
(>180 or<180 days of LVAD support), age, gender, BMI, etiology, and
Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS) profile. The mean duration to transplantation by era (early
2005-2008 and current 2009-2011) included patients who had undergone
transplantation and those awaiting transplantation. Those patients awaiting
transplantation were analyzed in the era in which they had received the
LVAD and were censored for the end of the study period.
Immunosuppression
A standard heart transplant immunosuppression protocol was imple-
mented at our center and was applied to all patients throughout the study
period. In patients with normal renal function, mycophenolate mofetil
1500 mg twice daily, tacrolimus 1 to 2 mg twice daily, and a 1-mg/kg initial
dose prednisone taper were initiated. The prednisone taper was typically
completed within 4 to 6 months after transplantation. If the patient had re-
nal dysfunction (glomerular filtration rate<30 mL/min/1.73 m2) for 3 days
after transplantation, an interleukin-2 receptor antagonist was used (dacli-
zumab was preferred until unavailable owing to product discontinuation,
with basiliximab used currently). The tacrolimus trough levels were576 The Journal of Thoracic and Cardiovascular Surgroutinely monitored, and the tacrolimus dose was adjusted to maintain
a therapeutic level, determined by the duration since transplantation.
Statistical Analysis
Weprospectively collected and retrospectively analyzed all the data. Con-
tinuous data are presented as themean standard deviation. Categorical data
are presented as percentages. Continuous data were compared using analysis
of variance or the t test, as indicated. The chi-square test or the Fisher exact
test was used for categorical variables. Survival estimates were determined
using the Kaplan-Meier method and compared using log-rank statistics. All
analyses were done using SPSS, version 12.0, software (SPSS, Chicago, Ill).RESULTS
Patient Characteristics
A total of 167 patients received a continuous-flow LVAD
as BTT during the study period at the University of Minne-
sota Medical Center. Of these patients, 77 underwent cardiac
transplantation (46%), 27 died before transplantation (16%),
and 63 (38%) remained listed for transplantation with ongo-
ing LVAD support. A comparison of the baseline characteris-
tics of the transplanted LVAD patients and those BTT
patients who still required LVAD support demonstrated that
the transplanted patients were older (54.5  12 vs 48  14
years, P¼ .006) and had a shorter duration of LVAD support
(310 227 vs 498 370 days,P¼ .017). No significant dif-
ferencewas found in gender, BMI, blood type, or etiology be-
tween the transplanted LVAD patients and those continuing
with LVAD support. The baseline characteristics of the trans-
planted patients versus those BTT patients who continued
with LVAD support are listed in Table 1.
The mean age of the transplanted patients was 54.5  12
years (range, 17-71 years). Most patients were men (n¼ 62,
80.5%). The etiology of heart failure in these patients was
ischemic in 44 (57%), nonischemic in 29 (38%), and other
in 4 (5%). Of the 77 patients, 55 received the HeartMate II
LVAD, 19 received the VentrAssist, and 3 received the
HVAD.Most patients were overweight, with a mean BMI of
29 kg/m2. Most patients had blood group A (43/77, 55.8%).
The baseline demographic characteristics of these 77
patients are summarized in Table 2.ery c February 2013
TABLE 2. Baseline demographic characteristics of patients bridged to
transplant with continuous-flow LVAD (n ¼ 77)
Variable Value
Age (y)
Mean  SD 54.5  12
Range 17-71
Male gender 62 (80.5)
Etiology
Ischemic 44 (57)
Nonischemic 29 (38)
Other 4 (5)
LVAD
HeartMate II 55
VentrAssist 19
HVAD 3
Duration of support (d)
Mean  SD 310  227
Range 67-1230
BMI (kg/m2) 29  5.6
Blood type (n ¼ 75)
Aþ 36
A 7
ABþ 1
Bþ 5
Oþ 22
O 4
INTERMACS profile
1 12
2 9
3 9
4 16
5 22
6 9
Renal function
Sodium 135  5
Creatinine 1.4  0.6
BUN 33  20
Liver function
ALT 81  236
AST 80  224
Total bilirubin 1.15  1.0
Data presented as mean standard deviation, n (%), or n. LVAD, Left ventricular as-
sist device; BMI, body mass index; INTERMACS, Interagency Registry for Mechan-
ically Assisted Circulatory Support; BUN, blood urea nitrogen; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; SD, standard deviation.
TABLE 3. Baseline and pretransplant hemodynamics
Variable
Pre-LVAD baseline
hemodynamics
Pretransplant
hemodynamics
P
value
Systolic blood pressure
(mm Hg)
108  18.4 108  18 .256
Diastolic blood pressure
(mm Hg)
70  11.2 81  14 .057
Right atrial pressure
(mm Hg)*
12  6 7  5 .001
Pulmonary artery systolic
pressure (mm Hg)*
55  14 35  12 <.001
Pulmonary artery diastolic
pressure (mm Hg)*
26  9 15  7 <.001
Mean pulmonary artery
pressure (mm Hg)*
37  9 22.5  9 <.001
Cardiac index (L/min m2)* 2.0  0.5 2.4  0.4 <.001
Cardiac output (L/min)* 4.2  1 4.9  1 .002
LVAD, Left ventricular assist device. *P<.05.
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XHemodynamics
The baseline hemodynamics and pretransplant hemody-
namics for these LVAD patients are listed in Table 3. Signif-
icant improvement was seen in the right atrial pressure,
pulmonary artery pressures, and cardiac output and index
among these patients with LVAD support.Post-Transplant Outcomes
Time to transplantation. The 77 transplanted patients had
a mean duration to transplantation after LVAD support of
310  227 days (range, 67-1230 days). The mean durationThe Journal of Thoracic and Cato transplantation according to the INTERMACS profile
was 343  297 days for INTERMACS 1 (crash and burn,
n ¼ 12), 365  284 days for INTERMACS 2 to 3 (inotrope
dependent, n ¼ 18), and 276  178 days for INTERMACS
4 to 7 (ambulatory, n ¼ 45; P ¼ NS).
Of the 77 patients, 62 were treated in the early era
(2005-2008), with a mean waiting time for transplantation
of 373  354 days, and 78 were treated in the current era
(2009-2011), with a mean waiting time for transplantation
of 392  262 days (P ¼ NS).
Transplantation for LVAD-related complications. Of
the 77 patients who were transplanted, 5 (6.5%) were listed
as United Network for Organ Sharing (UNOS) status 1A for
LVAD-related complications. These included the need for
inotropes in 2, frequent LVAD alarms with device malfunc-
tion in 2, and pump thrombus in 1. Only the patient with
pump thrombosis died 87 days after heart transplantation
of alveolar hemorrhage.
Of those patients who were initially implanted for BTT, 2
were excluded from the listing for transplantation because
of LVAD-related complications. One patient had a cerebro-
vascular accident and the other developed severe broncho-
malacia after LVAD implantation. These complications
resulted in exclusion from transplantation and designation
as destination therapy. In addition, a few patients were ini-
tially implanted with the intent for BTT but did not undergo
transplantation because of other non-LVAD–related issues
such as the development of malignancy or patient choice
to continue with LVAD support.
Survival. The 30-day operative survival for the trans-
planted patients was 98.7%. The 1-, 3-, and 5-year survival
by Kaplan-Meier analysis was 93.0%, 91.1%, and 88.0%,
respectively (Figure 1).
The post-transplant 1-year survival data stratified by
baseline demographics are listed in Table 4. No significant
difference was seen in 1-year survival between patients withrdiovascular Surgery c Volume 145, Number 2 577
FIGURE 1. Survival by Kaplan-Meier estimate for post-transplant pa-
tients after continuous-flow left ventricular assist device implantation.
TABLE 5. Death of patients transplanted after LVAD
Age (y),
gender Etiology
Duration
of LVAD
support (d)
Transplant
duration (d)
Cause of
death
35, Male Nonischemic 115 264 MSOF
65, Male Ischemic 112 1232 Respiratory failure
secondary to lung
adenocarcinoma
52, Male Ischemic 1129 125 Sepsis, MSOF
66, Male Nonischemic 199 217 MSOF
51, Male Ischemic 287 795 Cardiogenic
shock secondary to
antibody-mediated
rejection
63, Male Ischemic 487 97 Septic shock
62, Male Nonischemic 67 87 Alveolar hemorrhage
53, Male Ischemic 225 4 MSOF
LVAD, Left ventricular assist device; MSOF, multisystem organ failure.
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Xan ischemic or a nonischemic etiology (90.1% vs 93.2%,
P ¼ NS). No difference was seen in 1-year post-transplant
survival between men and women (90% vs 100%,
P ¼ NS). In evaluating post-transplant survival at 1 year
by age group, no significant difference was found among
patients younger than 50, 50 to 59, or older than 60 years
(100% vs 90.2% vs 92.9%, P ¼ NS). Similarly, noTABLE 4. Survival of post-LVAD transplant patients stratified by
demographics
Demographic Survival at 1 y P value
Etiology .89
Ischemic 90.1%
Nonischemic 93.2%
Gender .152
Male 90%
Female 100%
Age (y) .775
<50 100%
50-59 90.2%
>60 92.9%
BMI (kg/m2) .196
<29.9 95%
>30 87%
LVAD duration (d) .47
<180 88.5%
180 92.9%
INTERMACS profile .26
1 97.1%
2-3 100%
4-7 88.6%
LVAD, Left ventricular assist device; BMI, body mass index; INTERMACS, Inter-
agency Registry for Mechanically Assisted Circulatory Support.
578 The Journal of Thoracic and Cardiovascular Surgdifference was seen in survival between nonobese patients
(BMI< 30 kg/m2) and obese patients (BMI  30 kg/m2;
95% vs 87%, P ¼ NS). In addition, no difference was
seen in 1-year survival between those patients supported
with an LVAD for fewer than 180 days versus longer than
180 days before transplantation (88.5% vs 92.9%,
P ¼ NS). No difference was seen in 1-year-post transplant
survival according to the INTERMACS profile (1 [crash
and burn], 2-3 [ionotrope dependent], and 4-7 [ambulatory],
91.7%, 100%, and 88.6%, respectively; P ¼ NS).Post-Transplant Deaths
One patient died 4 days after transplantation of multisys-
tem organ failure. The other 7 deaths occurred 87 to 1232
days after transplantation. Only 1 death was secondary to
antibody-mediated rejection. The median time to death in
the transplanted patients was 212 days. The cause of death
for these patients is listed in Table 5; the cause of death for
the 27 patients who died after LVAD placement but before
transplantation is listed in Table 6.DISCUSSION
As mentioned, the discrepancy between the limited avail-
ability of donor hearts and the ever-increasing number of
patients with heart failure has led to the increasing use of
LVADs as a BTT. The therapeutic options and alternatives
for these patients needing an LVAD are limited. The deci-
sion to delay LVAD implantation and to support a patient
on the heart transplant waiting list with intravenous inotro-
pic therapy is often determined by a shorter expected wait-
ing time for a heart donor; the waiting time varies
considerably across the United States according to blood
group, body size, and other variables. In the current era,
the success in terms of improved survival, reduced adverse
events, and proven device durability reported for the currentery c February 2013
TABLE 6. Cause of death of LVAD BTT patients (n ¼ 27) who died before transplantation
Age, gender Etiology Support duration (d) Cause of death
Early mortality (<30 d; n ¼ 6)
23, Male Myocarditis 10 Subclavian vein hemorrhage
59, Male Ischemic 15 MSOF, vasoplegic shock
46, Male Ischemic 17 MSOF
53, Female Ischemic 28 Ventricular fibrillation arrest
66, Male Ischemic 30 MSOF
61, Male Ischemic 30 MSOF
Late mortality (>30 d; n ¼ 21)
57, Male Ischemic 32 MSOF
46, Female Giant cell myocarditis 33 Transtentorial herniation from intraparenchymal bleeding
56, Male Sarcoidosis 33 Withdrawal of care
54, Male Ischemic 42 Device failure
67, Male Nonischemic 73 MSOF
48, Male Nonischemic 89 Respiratory failure, withdrawal of care
44, Male Ischemic 92 MSOF, septic shock
60, Male Ischemic 133 Cardiopulmonary arrest
70, Male Ischemic 154 Pancreatic cancer
38, Male Nonischemic 157 Unknown
47, Male Ischemic 158 Unknown
61, Male Ischemic 188 Withdrawal of care
44, Male Ischemic 338 Respiratory failure
55, Male Ischemic 355 Intraparenchymal cranial bleeding
61, Male Ischemic 435 Intracranial hemorrhage
25, Female TGA 500 MSOF
68, Male Ischemic 560 Withdrawal of care
24, Female Viral dilated cardiomyopathy 644 MSOF, sepsis
69, Male Ischemic 1104 Withdrawal of care
49, Male Ischemic 369 Methamphetamine overdose
34, Female Nonischemic 1477 MSOF, sepsis
LVAD, Left ventricular assist device; BTT, bridge to transplant; MSOF, multisystem organ failure; TGA, transposition of great arteries.
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Xgeneration of continuous-flow devices has all but elimi-
nated the use of inotropes in most centers as an alternative
to an LVAD as a BTT. The use of mechanical circulatory
support as a BTT has evolved to become the standard of
care in most cardiac transplant programs. Furthermore, al-
though the results using LVADs as a BTT have been similar
to those for patients transplanted without LVAD support,
conflicting reports have been published on the effect of
LVADs on post-transplant survival.7-11 The findings from
the present study support the increasing evidence that
patients supported with continuous-flow LVADs have ac-
ceptable post-transplant survival. It appears that the excel-
lent hemodynamic, functional, and survival benefits
afforded by continuous-flow LVADs are closely linked to
the post-transplant survival benefits.5,14
The changes in the UNOS guidelines for heart organ
sharing to prioritize the use of donors primarily for status
1A patients have had a significant effect on the use of
LVADs for BTT. Patients who are status 1B are now
much less likely to receive a donor heart, and patients
who are status 2 rarely undergo heart transplantation. These
changes, as well as the continued increases in waiting times,
have contributed to the rapidly increasing use of LVADs.The Journal of Thoracic and CaAlthough the results with LVADs have consistently im-
proved over time, several questions remain with regard to
patient management and the optimal timing of cardiac
transplantation after the initiation of LVAD support.5,6
The decision to proceed with heart transplantation after
the initiation of LVAD support is guided partly by
variables not in full control of the transplant team, such as
donor availability, the UNOS policy for listing, and
patient-related variables such as blood group and body
size. Ultimately, the decision to proceed with active listing
lies with the transplant team, as does the decision to either
accept or refuse a donor heart for the potential recipient. In
recent years, significant UNOS policy changes affecting
LVAD BTT candidates have occurred because of outcomes
data from patients supported with pulsatile devices.15 It is
possible that additional changes will occur on the basis of
waiting list and post-transplant survival outcomes for pa-
tients supported with the newer generation continuous-
flow rotary devices.
The currently available data could have significant impli-
cations for changing the current UNOS criteria regarding
the listing of LVAD BTT candidates. In the previous Heart-
Mate XVE era, changes in UNOS policy significantlyrdiovascular Surgery c Volume 145, Number 2 579
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Xaffected the LVAD BTT candidates. Although additional
data with longer term follow-up are essential to make defin-
itive recommendations, the clinical outcomes data with
continuous-flow devices might suggest whether stable pa-
tients with the HeartMate II device should be listed as
UNOS status 1A in the absence of any LVAD-related com-
plications. A recent study demonstrated that the stability
achieved with implanted LVADs was much greater than
can be achieved among other subgroups of patients listed
as status 1A.16 The current 30-day period allocated to
LVAD patients listed as status 1A could result in competi-
tion between similarly listed patients but with very different
risks of death (eg, patients with intra-aortic balloon pump
support who might have a contraindication to an LVAD).
A more equitable change might allow for a status IA listing
for LVAD patients who have a device complication such as
a persistent infection or recurrent arrhythmias or who have
developed sensitization.16,17
The recent advent of continuous-flow LVADs has had an
important effect on survival and quality of life of patients
with advanced heart failure. Although steady improvements
have been reported for continuous-flowdevices, an important
observation in a post-trial study was a decrease in the per-
centage of patients undergoing heart transplantation from
the clinical trial to the post-trial periods.18 After 6 months
of LVAD support, 32% of patients had undergone transplan-
tation in the trial compared with only 22% of the post-trial
patients. Similarly, by 12 months, 48% of the trial patients
had received a transplant compared with 39% of the post-
trial patients. Not unexpectedly, the increased numbers of
continuous-flowdevices being implantedhas led to increased
competition for a limited number of donors, themajor reason
for the longer waiting time to transplantation. It remains un-
clear why an increased waiting time to transplantation was
not found during the latter part of the present study.
When the clinical trials with continuous-flow devices be-
gan just over 1 decade ago, concern was expressed regard-
ing the uncertainty of the long-term effects of systemic
arterial blood flow with low pulsatility. However, the large
amount of cumulative experience with continuous-flow de-
vices (primarily the HeartMate II) has indicated that long-
term support does not have obvious detrimental effects on
organ function. More relevant to the present study is a recent
report that a prolonged duration of support with continuous-
flow devices might be associated with greater hemody-
namic compromise, which was demonstrated by the need
for greater dose requirements and increased duration of
pressor support after restoration of pulsatility at transplanta-
tion.19 Although the later study showed no differences in
early post-transplant mortality compared with patients re-
ceiving pulsatile devices, some studies have noted differ-
ences in vascular tone and endothelial function in patients
supported with continuous-flow devices.20,21 Studies in
animal models have shown that the hemodynamic580 The Journal of Thoracic and Cardiovascular Surgconsequences of long-term nonpulsatile flow include dis-
ruption of the renin-angiotensin system and an altered re-
sponses to norepinephrine administration. Other studies
have shown histologic changes in arterial wall medial thick-
ness and changes in smooth muscle and elastin content dur-
ing continuous-flow device support.22,23 Nevertheless,
despite possible changes to vascular and endothelial
function, patients supported with continuous-flow devices
have had excellent outcomes after cardiac transplantation.
The durability and reliability of the LVAD design is, per-
haps, 1 of the most significant features for continued ex-
tended use of mechanical circulatory support devices.
Previous studies demonstrated limited durability and reli-
ability for the pulsatile HeartMate XVE LVAD, with nearly
50% of patients experiencing device exchange because of in-
fection or mechanical malfunction at 18 months.24 Very few
device replacements were required for device thrombosis,
malfunction, or infection in the multicenter study or in our
study. No mechanical failure of the device pumping mecha-
nism was observed.5,25 The absence of mechanical failure of
the pumping mechanism is significant and has not been
previously observed in trials evaluating older technology.
The remarkable durability of the HeartMate II LVAD can
allow for improved donor selection in contrast to the
pulsatile pump era in which decreasing durability beyond
the 1-year mark increased the urgency for transplantation
and the subsequent potential for suboptimal donor selection.
Study Limitations
Our single-center study was limited to a relatively
smaller number of patients compared with a multicenter
study and included 3 different types of continuous-flow de-
vices. Although recently published multicenter data have
shown evidence of the excellent post-transplant outcomes
for patients with continuous-flow devices, the strength of
the present study was the large number of patients undergo-
ing implantation at a single center with consistent perioper-
ative and postoperative management strategies. In addition,
donor selection and recipient listing algorithms are more
likely to be uniform at a single center. Although multicenter
studies do have strict inclusion and exclusion criteria and
guidelines for perioperative management, it is clear that
multiple areas exist for investigators to use strategies that
often differ at individual centers. Other limitations of the
present study included the lack of data on post-transplant
morbidity, such as rejection and infection.
In conclusion, the short- and mid-term post-transplant
survival of patients supported by continuous-flow LVADs
appears similar to the outcomes for non-LVAD BTT pa-
tients. In addition, no differences were seen in survival
among transplanted patients when stratified by etiology of
heart failure, gender, age, BMI, or duration of LVAD sup-
port. There is no reason, therefore, to support a hypothesis
that the reduced pulsatility during LVAD support adverselyery c February 2013
Kamdar et al Cardiothoracic Transplantationaffects post-transplant survival. Our single-center data add
to the increasing body of evidence that post-transplant sur-
vival for patients supported by continuous-flow devices is
excellent and supports the current standard of care that
continuous-flow devices are the primary therapeutic option
for patients with advanced heart failure.References
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